Gemini Therapeutics Inc (GMTX)


Stock Price Forecast

Jan. 9, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Gemini Therapeutics Inc chart...

About the Company

Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.

Exchange

NASDAQ

Website

geminitherapeutics.com

$1B

Total Revenue

29

Employees

$831M

Market Capitalization

-1.03

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $GMTX News

Google Gemini finally comes to older Android devices

1h ago, source:

Gemini, Google's rebranded language model, now supports Android 10 and 11, making it accessible to more users on the go.

Intellia Therapeutics Inc NTLA

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Google Gemini's conversation mode could make interactions with AI easier

on MSN ago, source:

Google is working on improving Gemini's response time to compete with Google Assistant on Android. Gemini could soon ...

Gemini AI is heading to older Android phones, and could get a new 'conversation' mode

on MSN ago, source:

Up until now, you've needed a phone running Android 12 or later to make use of the Google Gemini AI app for Android, but that ...

Seelos Therapeutics Inc SEEL

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Design Therapeutics, Inc.

11mon ago, source: CNN

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small ...

Google Gemini on Android could soon summarize PDFs and other files — here’s what you need to know

on MSN ago, source:

A recent report has indicated that Google could update the Google Gemini App on Android to allow uploads of more types of ...

Outlook Therapeutics, Inc. (OTLK)

2d ago, source: Yahoo Finance

ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of ...

Revance Therapeutics, Inc. (RVNC)

3d ago, source: Yahoo Finance

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...

The Samsung S25 Series May Come With Gemini Nano 2 Onboard

4h ago, source: talkandroid.com on MSN

Samsung doesn't plan to let up on the AI love with the S25 generation next year. The lineup should support Google's upcoming ...

Viking Therapeutics Inc (VKTX)

8d ago, source: Investing

On Tuesday, Viking Therapeutics (NASDAQ:VKTX) saw its price target increased by an Oppenheimer analyst to $138 from the previous $116, while the stock's rating remains at... On Tuesday, Viking ...

Intellia Therapeutics, Inc.

6mon ago, source: CNN

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...